318 related articles for article (PubMed ID: 25468677)
21. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S; Klar M; Matsuzaki S; Roman LD; Sood AK; Matsuo K
Gynecol Oncol; 2021 Feb; 160(2):586-601. PubMed ID: 33183764
[TBL] [Abstract][Full Text] [Related]
22. [Uterine Carcinosarcoma: Clinicopathological Features and Prognostic Factors].
Luz R; Ferreira J; Rocha M; Jorge AF; Félix A
Acta Med Port; 2016 Oct; 29(10):621-628. PubMed ID: 28103458
[TBL] [Abstract][Full Text] [Related]
23. [Uterine carcinosarcoma in a teenager: report of a case macroscopically mimicking rhabdomyosarcoma].
Rouas L; Regragui A; Oukabli M; Amrani M; Gamra L; Otmani A; Bellabas MA
Rev Med Liege; 2005 Dec; 60(12):911-4. PubMed ID: 16457389
[TBL] [Abstract][Full Text] [Related]
24. Uterine sarcoma-current management and experience from a regional cancer centre in North India.
Biswas A; Patel F; Kumar P; Srinivasan R; Bera A; Sharma SC; Rajwanshi A
Arch Gynecol Obstet; 2013 Oct; 288(4):873-82. PubMed ID: 23580012
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.
Kahramanoglu I; Demirkiran F; Turan H; Bese T; Cebi S; Ilvan S; Arvas M
J Obstet Gynaecol Can; 2021 Jan; 43(1):34-42. PubMed ID: 33041218
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant radiotherapy for uterine carcinosarcoma: A retrospective assessment of treatment outcomes.
Yilmaz U; Alanyali S; Aras AB; Ozsaran Z
J Cancer Res Ther; 2019; 15(6):1377-1382. PubMed ID: 31898676
[TBL] [Abstract][Full Text] [Related]
27. Uterine carcinosarcoma.
El-Nashar SA; Mariani A
Clin Obstet Gynecol; 2011 Jun; 54(2):292-304. PubMed ID: 21508698
[TBL] [Abstract][Full Text] [Related]
28. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II.
Visnovsky J; Kudela E; Slavik P; Krkoska M; Buocik P; Szepe P; Danko J
Neuro Endocrinol Lett; 2015; 36(8):750-7. PubMed ID: 26921575
[TBL] [Abstract][Full Text] [Related]
29. [Uterine carcinosarcoma].
Serkies K; Jassem J
Ginekol Pol; 2012 Aug; 83(8):609-12. PubMed ID: 23342885
[TBL] [Abstract][Full Text] [Related]
30. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
31. A population-based series of uterine carcinosarcomas with long-term follow-up.
Sorbe B; Paulsson G; Andersson S; Steineck G
Acta Oncol; 2013 May; 52(4):759-66. PubMed ID: 23072724
[TBL] [Abstract][Full Text] [Related]
32. [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors].
Horn LC; Dallacker M; Bilek K
Pathologe; 2009 Jul; 30(4):292-301. PubMed ID: 19495763
[TBL] [Abstract][Full Text] [Related]
33. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes.
Garg G; Shah JP; Kumar S; Bryant CS; Munkarah A; Morris RT
Int J Gynecol Cancer; 2010 Jul; 20(5):888-94. PubMed ID: 20606539
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
Etoh T; Nakai H
J Obstet Gynaecol Res; 2014 Mar; 40(3):820-5. PubMed ID: 24320058
[TBL] [Abstract][Full Text] [Related]
35. Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study.
Bodner-Adler B; Bodner K; Obermair A; Czerwenka K; Petru E; Leodolter S; Mayerhofer K
Anticancer Res; 2001; 21(4B):3069-74. PubMed ID: 11712812
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Pinto A; Mackrides N; Nadji M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
[TBL] [Abstract][Full Text] [Related]
37. Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival.
Odei B; Boothe D; Suneja G; Werner TL; Gaffney DK
Am J Clin Oncol; 2018 Aug; 41(8):784-791. PubMed ID: 28121642
[TBL] [Abstract][Full Text] [Related]
38. State of the science: Uterine sarcomas: From pathology to practice.
Shushkevich A; Thaker PH; Littell RD; Shah NA; Chiang S; Thornton K; Hensley ML; Slomovitz BM; Holcomb KM; Leitao MM; Toboni MD; Powell MA; Levine DA; Dowdy SC; Klopp A; Brown J
Gynecol Oncol; 2020 Oct; 159(1):3-7. PubMed ID: 32839026
[No Abstract] [Full Text] [Related]
39. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
Bansal N; Herzog TJ; Seshan VE; Schiff PB; Burke WM; Cohen CJ; Wright JD
Obstet Gynecol; 2008 Jul; 112(1):64-70. PubMed ID: 18591309
[TBL] [Abstract][Full Text] [Related]
40. [Sarcomas and mixed mesodermal tumors of the uterus].
Günthert AR
Ther Umsch; 2011 Oct; 68(10):559-64. PubMed ID: 21968895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
